Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Laurus Labs Ltd

| Quarterly Financial Results Q3 FY 2025-26

BULLISH SENTIMENT

Report Source

⬤23rd Jan 26

Summary : Laurus Labs reports strong Q3 and 9M FY26 consolidated financial results with significant profit growth, alongside strategic investments and a proposed demerger scheme.

Quarterly Report Analysis & Insights

Financial Disclosures

  1. Consolidated Cost of materials consumed: Q3 FY26: 725.32 Cr; 9M FY26: 2,001.48 Cr.
  2. Consolidated Employee benefits expense: Q3 FY26: 229.24 Cr; 9M FY26: 659.60 Cr.
  3. Consolidated Other expenses: Q3 FY26: 374.27 Cr; 9M FY26: 1,080.77 Cr.
  4. Standalone Cost of materials consumed: Q3 FY26: 649.72 Cr; 9M FY26: 1,867.01 Cr.
  5. Standalone Employee benefits expense: Q3 FY26: 196.29 Cr; 9M FY26: 558.50 Cr.
  6. Standalone Other expenses: Q3 FY26: 341.60 Cr; 9M FY26: 1,001.97 Cr.
  7. Consolidated Revenue from operations: Q3 FY26: 1,778.29 Cr; 9M FY26: 5,001.33 Cr.
  8. Consolidated Other income: Q3 FY26: 5.76 Cr; 9M FY26: 43.15 Cr.
  9. Standalone Revenue from operations: Q3 FY26: 1,509.42 Cr; 9M FY26: 4,508.77 Cr.
  10. Standalone Other income: Q3 FY26: 14.37 Cr; 9M FY26: 64.34 Cr.
  11. Investments in Laurus Bio Private Limited and KRKA Pharma Private Limited.
  12. Both standalone and consolidated unaudited financial results are presented.
  13. Consolidated results include subsidiaries, associates, and joint ventures.

Corporate Overview

  1. India (Parent, Subsidiaries, Associates, Joint Venture)
  2. United Kingdom (Subsidiary)
  3. United States of America (Step-down subsidiary)
  4. Germany (Step-down subsidiary)
  5. South Africa (Wholly Owned Subsidiary)
  6. Evaluating the full impact of new Labour Codes effective November 21, 2025.
  7. Monitoring finalization of Central/State Rules and Clarifications for Labour Codes.
  8. Engaged in the manufacture and sale of Pharmaceuticals.
  9. Operates as a single reportable business segment.
  10. Formal and compliant with regulatory disclosure requirements.
  11. Pharmaceuticals (single segment).
  12. Invested 35 Crores in Laurus Bio Private Limited.
  13. Made capital contribution of 49 Crores in KRKA Pharma Private Limited for 49% stake.
  14. Proposed Composite Scheme of Arrangement for demerger of Laurus Synthesis Private Limited.

Risk Factors

  1. New Labour Codes impact uncertain.
  2. Integration risks from demerger scheme.
  3. Reliance on other auditors' reports.
  4. Potential for unforeseen regulatory changes.

Key Drivers

  1. Strong revenue and profit growth.
  2. Strategic investments in key ventures.
  3. Proposed demerger for business restructuring.
  4. Unmodified audit opinion on results.

Auditor’s Report

  1. Unmodified conclusion on consolidated financial results.
  2. Unmodified conclusion on standalone financial results.
  3. Reliance on review reports of other auditors for five subsidiaries.
  4. Reliance on management certification for associates and joint ventures.

Board Commentary

  1. Noting of change in address of Corporate Office.
  2. Impact of new Labour Codes, with an estimated incremental liability of 8.3 Crores.
  3. Compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
  4. Evaluation of new Labour Codes and their incremental liability.
  5. Investment of 35 Crores in Laurus Bio Private Limited.
  6. Capital contribution of 49 Crores in KRKA Pharma Private Limited.
  7. Proposed Composite Scheme of Arrangement for demerger/amalgamation.

Corporate Governance

  1. Audit Committee reviewed and approved financial results.

Management Discussion & Analysis

Future Strategy

  1. Pursuing a Composite Scheme of Arrangement for business restructuring.
  2. Strategic investments in Laurus Bio and KRKA Pharma.

Operational Focus Areas

  1. Evaluating impact of new Labour Codes.
  2. Monitoring regulatory updates for Labour Codes.

Performance Drivers

  1. Significant growth in revenue from operations for the quarter and nine months.
  2. Substantial increase in net profit after tax compared to previous periods.

Risk Control Measures

  1. Actively evaluating new labour codes' impact.
  2. Monitoring finalization of rules and clarifications.

Critical Risks

  1. Uncertainty regarding the full impact of new Labour Codes.
  2. Potential complexities from the proposed demerger scheme.
Laurus Labs Ltd (LAURUSLABS) Quarterly Report Analysis & Insights | Dhanarthi